How to Care for the Patient With Methamphetamine-Associated PAH.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41819484.
- Also identified by DOI 10.1016/j.chest.2026.02.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Methamphetamine is a potent CNS stimulant that is highly addictive. Although methamphetamine use historically has been localized to the Western United States Census region, its reach has been growing, and methamphetamine use now is expanding throughout the United States and the world. Methamphetamine is now considered a definite cause of pulmonary arterial hypertension (PAH). Despite being one of the fastest growing causes of PAH, recommendations to guide the care of patients with methamphetamine-associated PAH have not been published. This review focuses on the care of patients with methamphetamine-associated PAH. It provides a practical approach to care that incorporates pharmacologic therapy in conjunction with harm reduction strategies as well as support from ancillary services such as addiction medicine and social work.